Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
about
BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysisMedication-Induced Tardive Dyskinesia: A Review and Update.Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report.An update on tardive dyskinesia: from phenomenology to treatmentCrocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanismTherapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation.A case of tardive dyskinesia in the last weeks of life.Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
P2860
Q33566832-70721081-86A7-403C-89F8-030A5C077225Q33802645-F9D2B3C3-3FA2-46C4-A03E-1D0964C89ED7Q35813662-E62148D3-773B-4C83-9E6A-FD5044550F8BQ37006021-F0EB9690-AD6A-440C-A14B-7A84A2A4CDFFQ37416345-6E1F623B-229B-44A4-9C2B-90ED156C34C1Q39084564-2880841B-9A4B-4190-A2BB-1F6955D5C295Q39187554-777E9B9C-9FAF-498D-9016-16BADD1E92CBQ54969812-159B28B3-2F39-4FFC-9802-25705AD9A427
P2860
Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
@en
type
label
Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
@en
prefLabel
Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.
@en
P1476
Oxidative stress and tardive dyskinesia: pharmacogenetic evidence
@en
P2093
Chul-Hyun Cho
P304
P356
10.1016/J.PNPBP.2012.10.018
P577
2012-10-31T00:00:00Z